<DOC>
	<DOCNO>NCT02586194</DOCNO>
	<brief_summary>The objective study compare evaluate pharmacokinetics ASP015K patient impaired hepatic function subject normal hepatic function .</brief_summary>
	<brief_title>Pharmacokinetics Study Patients With Impaired Hepatic Function</brief_title>
	<detailed_description />
	<criteria>A subject eligible study follow apply : All subject : Body weight : ≥40.0 kg &lt; 90.0 kg Body mass index ( BMI ) : ≥17.0 &lt; 30.0 kg/m2 Female subject must either : Be postmenopausal surgically sterile . Agree try become pregnant starting time inform consent throughout study period 60 day final study drug administration childbearing potential . Agrees use highly effective contraception Agrees donate sperm ( male ) / ovum ( female ) start time informed consent , throughout study period 90/60 day final study drug administration . Female subject agrees breastfeed start time informed consent , throughout study period 60 day final study drug administration . Agrees participate clinical trial , postmarketing study , clinical study period inform consent post examination . A patient impaired hepatic function : Impaired hepatic function ChildPugh Score Class A ( mild , 56 point ) Class B ( moderate , 79 point ) . A subject normal hepatic function : Healthy , judge investigator/subinvestigator base physical examination test obtain screen period hospital admission immediately study drug administration . A subject exclude participation study follow apply : All subject : Received scheduled receive investigational drug clinical trial , postmarketing study clinical research within 120 day screen period screen hospital admission . Excessive alcohol smoking habit . Applies follow concern tuberculosis : A history active tuberculosis Abnormalities detect chest Xray test ( screen ) Contact infectious tuberculous patient Applies follow concern except tuberculosis : Concurrent previous severe herpes zoster herpes zoster disseminate More 1 recurrence localize herpes zoster Inpatient hospital care severe infectious disease within 90 day hospital admission Treatment intravenous antibiotic within 90 day hospital admission ( prophylactic antibiotic applicable ) Other , people risk develop infectious disease ( e.g . urethral catheterisation ) judgment investigator/subinvestigator Vaccination live vaccine live attenuate vaccine within 56 day hospital admission ( inactivated vaccine influenza vaccine pneumococcal vaccine applicable ) . Concurrent previous drug allergy . A history clinically serious allergy ( serious allergy : Generalised urticaria require hospital admission , allergy cause anaphylactic shock , etc. ) . Concurrent previous cardiac failure NYHA class 3 4 , long QT syndrome congenital short QT syndrome . Development ( ) upper gastrointestinal symptom ( ) within 7 day hospital admission . Concurrent previous lymphatic disease . A history digestive tract excision , except history appendectomy . Previous use ASP015K . A patient impaired hepatic function : Unable start washout concomitant prohibit medication least 14 day prior study drug administration . Concurrent uncontrolled hypertension . Clinically significant abnormality detect standard 12lead electrocardiogram screening hospital admission . eGFR GFR estimate equation Japanese &lt; 45 mL/min/1.73 m2 ( first decimal place round ) screening . Uncontrolled ascites pleural effusion observe screening . Concurrent hepatic encephalopathy Coma Scale II screening . Underwent hepatic transplantation , underwent hepatectomy within 1 year screening . Concurrent previous druginduced hepatic disorder . Concurrent acute hepatic disease . With surgicallyplaced portosystemic shunt include transjugular intrahepatic portosystemic shunt . Concurrent biliary obstruction . A history oesophageal haemorrhage gastric varix haemorrhage within 180 day screen . Irregular acute , clinically significant LFT value change clinical symptom 30 day screen immediately study drug administration . Platelet count &lt; 4 × 104/μL , haemoglobin &lt; 9 g/dL screening . Alcohol dependence unable remain abstinent specified period . Concurrent esophagus gastric varix high risk clinically significant haemorrhage . Concurrent cerebrovascular disorder , serious heart disease , malignant tumour history within 5 year screen , gastrointestinal disease , urinary disease , renal disease , endocrine disease , respiratory disease . A subject normal hepatic function : Received scheduled receive medication ( include overthecounter drug ) within 7 day hospital admission . Deviates normal range blood pressure , pulse rate , body temperature standard 12lead electrocardiogram screening hospital admission . Meets criteria laboratory test screen hospital admission . eGFR GFR estimate equation Japanese &lt; 60 mL/min/1.73 m2 ( first decimal place round ) screening . Concurrent previous hepatic disease , cerebrovascular disorder , malignant tumor , heart disease , gastrointestinal disease , except history appendicitis , renal disease , endocrine disease , respiratory disease , urological disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Impaired hepatic function</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>ASP015K</keyword>
</DOC>